Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily

Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily

Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily

The number of subjects achieving HbA1c reductions of > 0.5% and > 1.0% by study termination (Week 30)

The time it takes subjects to achieve HbA1c reductions of 0.5% or more and >1.0% or more

The time it takes subjects to achieve HbA1c target values of < 7% and < 8%

Change in body weight (kg) from Baseline to each intermediate visit and Week 30